Articles

‘Dr. Doom’ Nouriel Roubini: ‘Worst-case scenarios appear to be the least likely.’ For now.

Fed may achieve a 'soft landing' for the U.S. economy.

Government shutdown? Chances are ‘way down’ after spending deal, but ‘not to zero,’ analyst says

A shutdown "remains possible," but there are signs of progress.

Solo Stove’s stock on track for its largest-ever one-day loss on heels of revenue warning

Smokeless-firepit maker also named former chief executive of Vista Outdoor as its new president and chief executive.

Bitcoin ETF: Here are the 10 funds set to debut after SEC decision

No less than 10 fund companies have filed the necessary paperwork to launch a spot bitcoin exchange-traded fund (ETF) and await a final decision from U.S. financial regulators on whether they can start trading this week.

UBS joins Wall Street strategists calling for new S&P 500 record in 2024

A team of strategists at UBS Group's wealth-management arm has lifted its 2024 price target for the S&P 500, joining a growing chorus on Wall Street that expects stocks to reach record territory before the end of the year.

Housing sentiment jumps as nearly a third of Americans believe mortgage rates will fall in the coming year

Consumer optimism rose on the back of expectations around rates falling, a new Fannie Mae survey shows.

3M to freeze pensions for non-union employees

3M Co. said Monday that it plans to end its pension plan for non-union U.S. employees in five years.

State schools like Michigan and Washington dominate more than the football field

‘Public colleges have been the bellwether’ for debates over free speech and the value of a college degree

Lululemon Athletica’s Q4 guidance edges up but low end of range could fall a penny short of FactSet consensus estimate

Company boosts outlook but may slightly miss Wall Street's earnings mark.

Uh-oh: Everyone is back to buying stocks again.

Retail investors are falling back into a bad habit of following a herd.

Oil futures slump as Saudis cut prices

Oil futures start the week with a tumble as Saudi price cuts underline fears about demand.

Merck to pay 118% premium to buy cancer drugmaker Harpoon Therapeutics

Merck announced Monday an agreement to buy cancer treatment developer Harpoon Therapeutics in a deal valued at $680 million.
1 1,711 1,712 1,713 1,714 1,715 2,429